Changes in hepatic transaminases among children with COVID-19 in Najaf city

Background. In December 2019, 54 cases of viral pneumonia of unknown cause emerged in Wuhan, China. The causative agent was later identified as a novel coronavirus producing severe acute respiratory syndrome, subsequently named SARS-CoV-2 (COVID-19). The infection has since spread worldwide, affecting all age groups and causing multi-organ involvement. The purpose was to study changes in liver enzymes in relation to demographic variables, clinical course, and severity among hospitalized children with COVID-19. Materials and methods. This cross-sectional retrospective study included 50 confirmed pediatric COVID-19 cases aged 18 years or younger who were admitted to one of three hospitals in Najaf city after confirmation by real-time polymerase chain reaction from March 2020 to March 2021. Cases were classified as mild-to-moderate or severe according to the seventh trial version of the National Health Commission program. Demographic data, history, physical findings, and investigations were collected from all patients’ files. Liver function tests were recorded for all children. Associations between the clinical and demographic variables and liver enzyme levels were examined using bivariate tests only. No a priori sample size calculation was performed, and no multivariable modelling was undertaken, so the analysis is exploratory. Results. Among the 50 confirmed cases, severe disease was found in 21 patients (42 %), whereas 29 (58 %) had mild-to-moderate course. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were analyzed in relation to the clinical variables. Mean ALT and AST were higher in severe than in mild-to-moderate disease (p = 0.001 and p = 0.05, respectively) and in children who died than in those whose illness resolved (p < 0.001 and p = 0.013, respectively). Both enzymes positively correlated with length of stay (r = 0.54 for ALT and r = 0.23 for AST). ALP was not associated with severity (p = 0.556), length of stay, or outcome (p = 0.745). All estimates are unadjusted. Conclusions. In this retrospective study, higher ALT and AST levels were associated with more severe disease and a fatal outcome. Because the design is cross-sectional and the estimates are unadjusted, these findings describe associations only and do not establish that COVID-19 caused the enzyme changes. Severe disease was seen in every age group. Both toddlers in the sample had severe illness, but two children are far too few to support any conclusion about age-specific risk. The study should be read as exploratory and hypothesis-generating.

Authors

Institutions

Publication Details

Journal
CHILD`S HEALTH
Published
2026-11-12
DOI
https://doi.org/10.22141/2224-0551.21.7.2026.1976
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Changes in hepatic transaminases among children with COVID-19 in Najaf city

Alaa Jumaah Manji Nasrawi, Hiba S.M.H. Al-Maqdisi, M. Jafar Zainldeen, Jasim Mohammed Hashim Al-Musawi
CHILD`S HEALTH
COVID-19 Clinical Research Studies
article

Changes in hepatic transaminases among children with COVID-19 in Najaf city

Alaa Jumaah Manji Nasrawi, Hiba S.M.H. Al-Maqdisi, M. Jafar Zainldeen, Jasim Mohammed Hashim Al-Musawi
article en

Abstract

Background. In December 2019, 54 cases of viral pneumonia of unknown cause emerged in Wuhan, China. The causative agent was later identified as a novel coronavirus producing severe acute respiratory syndrome, subsequently named SARS-CoV-2 (COVID-19). The infection has since spread worldwide, affecting all age groups and causing multi-organ involvement. The purpose was to study changes in liver enzymes in relation to demographic variables, clinical course, and severity among hospitalized children with COVID-19. Materials and methods. This cross-sectional retrospective study included 50 confirmed pediatric COVID-19 cases aged 18 years or younger who were admitted to one of three hospitals in Najaf city after confirmation by real-time polymerase chain reaction from March 2020 to March 2021. Cases were classified as mild-to-moderate or severe according to the seventh trial version of the National Health Commission program. Demographic data, history, physical findings, and investigations were collected from all patients’ files. Liver function tests were recorded for all children. Associations between the clinical and demographic variables and liver enzyme levels were examined using bivariate tests only. No a priori sample size calculation was performed, and no multivariable modelling was undertaken, so the analysis is exploratory. Results. Among the 50 confirmed cases, severe disease was found in 21 patients (42 %), whereas 29 (58 %) had mild-to-moderate course. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were analyzed in relation to the clinical variables. Mean ALT and AST were higher in severe than in mild-to-moderate disease (p = 0.001 and p = 0.05, respectively) and in children who died than in those whose illness resolved (p < 0.001 and p = 0.013, respectively). Both enzymes positively correlated with length of stay (r = 0.54 for ALT and r = 0.23 for AST). ALP was not associated with severity (p = 0.556), length of stay, or outcome (p = 0.745). All estimates are unadjusted. Conclusions. In this retrospective study, higher ALT and AST levels were associated with more severe disease and a fatal outcome. Because the design is cross-sectional and the estimates are unadjusted, these findings describe associations only and do not establish that COVID-19 caused the enzyme changes. Severe disease was seen in every age group. Both toddlers in the sample had severe illness, but two children are far too few to support any conclusion about age-specific risk. The study should be read as exploratory and hypothesis-generating.

CHILD`S HEALTHVol. 21(7)
University of Alkafeel (IQ), Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences (IQ), University of Kufa (IQ)
Good health and well-being
COVID-19 Clinical Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon